IPO - Denali Therapeutics Inc.

Form Type: S-3ASR

Filing Date: 2025-02-27

Corporate Action: Ipo

Type: New

Accession Number: 000162828025008647

Filing Summary: On February 27, 2025, Denali Therapeutics Inc. filed a registration statement on Form S-3ASR with the SEC. This registration statement allows for the offering, sale, and issuance of up to $400 million of common stock. The company has entered into an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the sale of these shares. The filing replaces a prior equity distribution agreement, maximizing the potential resources available to the company. Denali Therapeutics is focused on the development of therapies for neurodegenerative diseases, and the offering will be made through various channels including direct sales, agents, and possibly underwriters. The last reported sale price of Denali's common stock was $19.20 per share on February 25, 2025. The filing emphasizes the associated risks of investing in the company’s securities, as per the risk factors section included in the prospectus.

Document Link: View Document